NVNO logo

ENVVENO MEDICAL CORP

NVNONASDAQ
๐Ÿ† #5029 by market capEarnings Mar 25US Equity
$5.25โ–ผ $0.32 (โˆ’5.75%)
Market closed ยท at close
๐Ÿ””
Track NVNO
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 5.8%
7dโ–ผ 21.9%
14dโ–ผ 21.4%
30dโ–ผ 30.4%
ytdโ–ผ 52.6%
1yโ–ผ 54.7%
๐ŸฆMarket Cap
$4M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
0.0%
Slowing
๐Ÿ“ŠGross Margin
0.0%
Thin
๐Ÿ’ตFCF Margin
0.0%
Thin
โš–๏ธP/S Ratio
0.0x
Cheap
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$5.22 โ€“ $5.76
52-Week Range
$5.22 โ€“ $14.89
Volume (shares)
10,355
Avg Volume (shares)
โ€”
Shares Outstanding
694,826
Next Earnings
2027-03-25

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-22.41
Dividend Yield
0.00%
Dilution (1yr)
โˆ’1.1%
NVNO logo

ENVVENO MEDICAL CORP

NVNO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnโ€™t profitable yet.
โˆ’$21Mโ–ผ โˆ’12.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
โˆ’$16Mโ–ผ โˆ’7.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerโ€™s slice.
16Kโ–ผ โˆ’1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2Mโ–ฒ +$2M YoY
StockOtter ยท stockotter.space

About ENVVENO MEDICAL CORP

enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿ’งDilutionโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates